IMPORTANCE: Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized. We performed the first systematic review and meta-analysis of carfilzomib-associated CVAE. OBJECTIVE: To determine the incidence of carfilzomib-associated CVAE and to compare the rates of carfilzomib CVAE among different doses and companion therapies. DATA SOURCES: PubMed, EMBASE, Web of Science, and clinicaltrials.gov were queried for the keywords "carfilzomib," "Kyprolis," and "PX-171" through January 1, 2017. STUDY SELECTION: Phase 1 to 3 prospective clinical trials of carfilzomib in patients with multiple myeloma with evaluable toxic effects data were eligible for meta-analysis. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted by 2 reviewers following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Pooled incidence rates and relative risks (for randomized trials) and 95% confidence intervals were calculated using a random effects model. Subgroup analyses were performed to assess study-level characteristics associated with CVAE. MAIN OUTCOMES AND MEASURES: Cardiovascular adverse events were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and grades 3 or higher AEs and study characteristics were recorded. RESULTS: A total of 514 studies were assessed for eligibility. Of those, 24 studies were eligible, including a total of 2594 patients with multiple myeloma. All-grade and grades 3 and higher CVAE were seen in 617 (18.1%) and 274 (8.2%), respectively. Phase 2 or 3 studies and carfilzomib doses of 45 mg/m2 or higher were associated with high-grade CVAE. Median age older than 65 years, prior myeloma therapies, and concurrent myeloma therapies were not associated with CVAE. For the 3 randomized clinical trials, the summary relative risk of all-grade and grade 3 or higher CVAE for patients receiving carfilzomib compared with noncarfilzomib-receiving control patients were 1.8 and 2.2, respectively. CONCLUSIONS AND RELEVANCE: Carfilzomib was associated with a significant incidence of CVAE, with higher rates seen with higher doses of carfilzomib. Phase 1 studies may be underdetecting CVAE. Future studies are needed to identify patients at high risk for CVAE, develop optimal monitoring strategies, and explore strategies to mitigate these risks.
IMPORTANCE: Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized. We performed the first systematic review and meta-analysis of carfilzomib-associated CVAE. OBJECTIVE: To determine the incidence of carfilzomib-associated CVAE and to compare the rates of carfilzomib CVAE among different doses and companion therapies. DATA SOURCES: PubMed, EMBASE, Web of Science, and clinicaltrials.gov were queried for the keywords "carfilzomib," "Kyprolis," and "PX-171" through January 1, 2017. STUDY SELECTION: Phase 1 to 3 prospective clinical trials of carfilzomib in patients with multiple myeloma with evaluable toxic effects data were eligible for meta-analysis. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted by 2 reviewers following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Pooled incidence rates and relative risks (for randomized trials) and 95% confidence intervals were calculated using a random effects model. Subgroup analyses were performed to assess study-level characteristics associated with CVAE. MAIN OUTCOMES AND MEASURES: Cardiovascular adverse events were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and grades 3 or higher AEs and study characteristics were recorded. RESULTS: A total of 514 studies were assessed for eligibility. Of those, 24 studies were eligible, including a total of 2594 patients with multiple myeloma. All-grade and grades 3 and higher CVAE were seen in 617 (18.1%) and 274 (8.2%), respectively. Phase 2 or 3 studies and carfilzomib doses of 45 mg/m2 or higher were associated with high-grade CVAE. Median age older than 65 years, prior myeloma therapies, and concurrent myeloma therapies were not associated with CVAE. For the 3 randomized clinical trials, the summary relative risk of all-grade and grade 3 or higher CVAE for patients receiving carfilzomib compared with noncarfilzomib-receiving control patients were 1.8 and 2.2, respectively. CONCLUSIONS AND RELEVANCE: Carfilzomib was associated with a significant incidence of CVAE, with higher rates seen with higher doses of carfilzomib. Phase 1 studies may be underdetecting CVAE. Future studies are needed to identify patients at high risk for CVAE, develop optimal monitoring strategies, and explore strategies to mitigate these risks.
Authors: Michael Wang; Tom Martin; William Bensinger; Melissa Alsina; David S Siegel; Edward Kavalerchik; Mei Huang; Robert Z Orlowski; Ruben Niesvizky Journal: Blood Date: 2013-09-06 Impact factor: 22.113
Authors: Vivek Narayan; Stephen Keefe; Naomi Haas; Le Wang; Igor Puzanov; Mary Putt; Anna Catino; James Fang; Neeraj Agarwal; David Hyman; Amanda M Smith; Brian S Finkelman; Hari K Narayan; Steven Ewer; Chantal ElAmm; Daniel Lenihan; Bonnie Ky Journal: Clin Cancer Res Date: 2017-02-14 Impact factor: 12.531
Authors: Joseph R Mikhael; Craig B Reeder; Edward N Libby; Luciano J Costa; P Leif Bergsagel; Francis Buadi; Angela Mayo; Sravan K Nagi Reddy; Katherine Gano; Amylou C Dueck; A Keith Stewart Journal: Br J Haematol Date: 2015-02-13 Impact factor: 6.998
Authors: Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng Journal: Lancet Oncol Date: 2015-12-05 Impact factor: 41.316
Authors: David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: Syst Rev Date: 2015-01-01
Authors: Carol Chen-Scarabelli; Giovanni Corsetti; Evasio Pasini; Francesco S Dioguardi; Gagan Sahni; Jagat Narula; Mara Gavazzoni; Hemang Patel; Louis Saravolatz; Richard Knight; Riccardo Raddino; Tiziano M Scarabelli Journal: EBioMedicine Date: 2017-05-23 Impact factor: 8.143
Authors: Ajai Chari; Joaquín Martinez-Lopez; María-Victoria Mateos; Joan Bladé; Lotfi Benboubker; Albert Oriol; Bertrand Arnulf; Paula Rodriguez-Otero; Luis Pineiro; Andrzej Jakubowiak; Carla de Boer; Jianping Wang; Pamela L Clemens; Jon Ukropec; Jordan Schecter; Sagar Lonial; Philippe Moreau Journal: Blood Date: 2019-05-21 Impact factor: 22.113
Authors: G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta Journal: Pharmacol Ther Date: 2020-05-19 Impact factor: 12.310
Authors: Janice M Bonsu; Avirup Guha; Lawrence Charles; Vedat O Yildiz; Lai Wei; Brandee Baker; Jonathan E Brammer; Farrukh Awan; Maryam Lustberg; Raquel Reinbolt; Eric D Miller; Hani Jneid; Patrick Ruz; Rebecca R Carter; Michael W Milks; Electra D Paskett; Daniel Addison Journal: J Am Coll Cardiol Date: 2020-02-18 Impact factor: 24.094
Authors: Huan Wang; Robert P Sheehan; Adam C Palmer; Robert A Everley; Sarah A Boswell; Noga Ron-Harel; Alison E Ringel; Kristina M Holton; Connor A Jacobson; Alison R Erickson; Laura Maliszewski; Marcia C Haigis; Peter K Sorger Journal: Cell Syst Date: 2019-05-08 Impact factor: 10.304
Authors: Jorge J Castillo; Kirsten Meid; Catherine A Flynn; Jiaji Chen; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Guang Yang; Zachary Hunter; Steven P Treon Journal: Blood Adv Date: 2020-08-25